Optimizing Outcomes for Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Most patients diagnosed with breast cancer have a subtype that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). While this form of breast cancer is generally highly treatable in its earlier stages, some patients will unfortunately develop metastatic disease. However, the treatment landscape for HR+, HER2- metastatic breast cancer has seen significant advancements in recent years, with the introduction of new therapies that improve both quality of life and progression-free survival. These treatment options include endocrine therapies, CDK4/6 inhibitors, and antibody-drug conjugates (ADCs).

As the number of promising treatment options expands, it remains a challenge for community oncology providers to stay abreast of the latest and most effective management strategies for their patients. To address this need, the Association of Cancer Care Centers (ACCC) has launched an educational initiative to equip community oncology providers with up-to-date education and information about evidence-based practices for managing HR+, HER2- metastatic breast cancer.